Androgen receptor status predicts development of brain metastases in ovarian cancers

Gloria Mittica1,2,*, Rebecca Senetta3,*, Giulia Scotto1, Massimo Aglietta1,2, Furio Maggiorotto4, Eleonora Ghisoni1,2, Sofia Genta1,2, Renzo Boldorini5, Claudia Manini6, Isabella Morra7, Roberta Buosi8, Anna Sapino3,9, Paola Cassoni9,* and Giorgio Valabrega1,2,*

1Department of Oncology, University of Turin, Turin, Italy
2Division of Medical Oncology-1, Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy
3Unit of Pathology Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy
4Division of Gynecologic Oncology, Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy
5Department of Health Science, University of Eastern Piedmont "Amedeo Avogadro", Novara, Italy
6Unit of Pathology, Giovanni Bosco Hospital, Turin, Italy
7Unit of Pathology, Città della Salute e della Scienza, Turin, Italy
8Division of Oncology, Santo Spirito Hospital, Casale Monferrato, Italy
9Department of Medical Sciences, University of Turin, Turin, Italy
*These authors have contributed equally to this work

Correspondence to: Giorgio Valabrega. email: giorgio.valabrega@ircc.it
Keywords: androgen receptor, ovarian cancer, brain metastases

Received: November 24, 2016 Accepted: March 17, 2017 Published: April 12, 2017

ABSTRACT

Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR), human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a “Control dataset” of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry for Cases (both primary and metastatic lesions) and Controls.

Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively).

In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.
INTRODUCTION

Epithelial ovarian cancer (EOC) is the first cause of death among women with gynaecological malignancies [1]. In its natural history, this tumor tends to remain localized in the abdomen and pelvis even in advanced stage of disease, whereas haematogenous spread is a late event [2]. In fact, distant metastases account for approximately 16% of cases, and pleura (33%), liver (26%) and lung (3%) are the most common sites of tumor progression [3]. Central nervous system (CNS) involvement is a very uncommon and late event with an incidence ranging from 0.29 to 12% according to different series [3-6]. More recently, an increase in metastatic CNS involvement has been reported [5, 7, 8], probably reflecting prolonged patients’ survival related to improved surgery, radiotherapy and medical treatments [3, 4, 6, 8-14]. Several favorable prognostic factors have been identified such as younger age at time of diagnosis, Karnofsky PS, absence of extracranial lesions or solitary brain lesion [4, 6, 8-14]. However, prognosis remains globally unfavourable with a median overall survival (OS) of about 9.6 months for patients treated with only best supportive care, and 20.5 months for those undergoing multimodal treatments [13]. Clearly, early detection of CNS involvement may enhance the possibility of successfully treating these patients.

Hormonal receptor status (Estrogen Receptor-ER, Progesterone Receptor-PR and Androgen Receptor-AR) and Epidermal growth factor receptor 2 (HER2) status have been widely investigated as potential prognostic parameters in EOC patients, but reported results are controversial [15-22].

The aims of our study were the following: i) to define a possible association between ER, PR, AR, and HER2 with CNS progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOCs and their matched resected brain metastases.

RESULTS

Patients

Case dataset. The clinical and pathological features of primary ovarian lesions of the Case dataset are summarized in Table 1. Briefly, patient’s median age was 61 years and according to the FIGO classification there were 2/11 (18%) stage II, 6/11 (55%) stage III, and 3/11 (27%) stage IV patients. Up-front surgery was performed in 9 cases (82%) and in 7 patients (64%) a macroscopic residual tumor was assessed; most of the cases were high-grade serous adenocarcinoma with solid and papillary features (82%). All patients underwent adjuvant platinum-based chemotherapy. At the time of statistical analysis (June 2016), 3 of 11 (27%) patients were alive, whereas the remaining 7 patients (64%) had died; one patient was lost. The first site of relapse was brain in 7/11 (64%) cases, followed by lymph node (3/11, 27%); other sites included liver and mediastinum. All patients developed a CNS metastasis (median age: 62 years) with a median bPFS of 23 months (range 11-68). The majority of cases showed a single CNS metastasis (73%, 8/11) localized in cerebral hemispheres and, specifically, frontal lobe represented the most common localization (45%, 5/11). Surgical CNS treatment consisted of gross total or incomplete resection followed by systemic chemotherapy (Pegylated liposomal doxorubicin and Vinorelbine, oral Topotecan, Pegylated liposomal doxorubicin alone, Carboplatinum and Gemcitabine) in 4 patients (36%), loco-regional treatments as Whole Brain Radiotherapy (WBRT) in 64% (7/11) and stereotactic radiotherapy in 9% of cases (1/11). The bOS was 7 months (range 3-64). Table 2 reports the clinical parameters of the 11 cases with CNS metastases.

Control dataset. This subgroup included 22 patients with a median age at primary ovarian cancer diagnosis of 65.5 years (range 36-76). At diagnosis, 12/22 presented a FIGO stage III (55%), 6/22 (27%) a FIGO stage IV and 4/22 (18%) a FIGO stage II. All patients had a histological diagnosis of serous ovarian cancer. Twelve out of 22 (55%) cases underwent neoadjuvant platinum-based chemotherapy (NACT) followed by Interval Debulking Surgery (IDS); the remaining cases had up-front surgery; in 15/22 patients (68%) the surgery resulted suboptimal with a macroscopic residual tumor. All patients underwent adjuvant platinum-based chemotherapy. Seventeen (77%) patients experienced a progression disease with a median PFS of 16 months (range 4-73). Specifically, the most frequent sites of relapse were peritoneum and/or lymph nodes (88%, 15/17). The OS was 38.5 months (range 6-82) and, at the time of statistical analysis, 13/22 (59%) patients were dead. Table 1 resumes the main clinico-pathological features of Control dataset.

The two subgroups (Case and Controls) resulted homogeneous and comparable. There were not statistically significant differences for age (p = 0.323), tumor grade (p=1), stage of disease (p=1), type of surgery (p= 0.067), histotype (p=0,12) residual disease after surgery (p=0,9), (Table 1).

Immunohistochemical results

All cases of both datasets were evaluated by immunohistochemistry, but we had necessarily to exclude one case of primary ovarian cancer in the Case dataset as patient underwent NACT with a good pathological tumor response (only a sub-millimetric focus of residual carcinoma was found on histological specimen, insufficient to correctly evaluate immune-histochemical analyses). Table 3a reports immunohistochemical results of Case (both primary and CNS metastasis) and Control dataset, considered as dichotomized variables, whereas Table 3b and Table 4 as continuous variables.
| Clinico-histopathological parameters          | Case dataset (N=11) (%) | Control dataset (N=22) (%) | P     |
|----------------------------------------------|-------------------------|----------------------------|-------|
| Age, median (years) [range]                  | 61 [44-72]              | 65.5 [36-76]               | 0.323 |
| **Histological type**                        |                         |                            |       |
| Serous                                       | 9 (82)                  | 22 (100)                  | 0.12  |
| Endometrioid                                 | 2 (18)                  | 0 (0)                     |       |
| **Histological grade**                       |                         |                            |       |
| G2                                           | 1 (9)                   | 2 (9)                     | 1     |
| G3                                           | 10 (91)                 | 20 (91)                   |       |
| **FIGO Stage**                               |                         |                            |       |
| II                                           | 2 (18)                  | 4 (18)                    |       |
| III                                          | 6 (55)                  | 12 (55)                   | 1     |
| IV                                           | 3 (27)                  | 6 (27)                    |       |
| **Type of surgery**                          |                         |                            |       |
| Up-front                                     | 9 (82)                  | 10 (45)                   | 0.067 |
| Neoadjuvant CT + IDS                         | 2 (18)                  | 12 (55)                   |       |
| **Macroscopic residual tumor**               |                         |                            |       |
| Present                                      | 7 (64)                  | 15 (68)                   |       |
| Absent                                       | 3 (27)                  | 7 (32)                    | 0.9   |
| Not available                                | 1 (9)                   | 0 (0)                     |       |
| **First-line chemotherapy**                  |                         |                            |       |
| Platinum-based                               | 11 (100)                | 22 (100)                  | 1     |
| Other                                        | 0 (0)                   | 0 (0)                     |       |
| **Relapse**                                  |                         |                            |       |
| Present                                      | 11 (100)                | 17 (77)                   | 0.143 |
| Absent                                       | 0 (0)                   | 5 (23)                    |       |
| **First site of relapse**                    |                         |                            |       |
| Brain                                        | 7 (64)                  | 0 (0)                     |       |
| Lymph nodes and/or peritoneum other          | 3 (27)                  | 15 (88)*                  | 0.001 |
| **Patient’s status**                         |                         |                            |       |
| Alive                                        | 3 (27)                  | 9 (41)                    |       |
| Dead                                         | 7 (64)                  | 13 (59)                   | 0.301 |
| Not available                                | 1 (9)                   | 0 (0)                     |       |
| **PFS, median (months) [range]**             | 22 [7-50]               | 16 [4-73]                 |       |
| **OS, median (months) [range]**              | 47 [17-110]             | 38.5 [6-82]               |       |

* In 5 patients a progression disease was not evident.
IDS: Interval Debulking Surgery; CT: Chemotherapy; PFS: Progression Free Survival; OS: Overall Survival.
Table 2: Clinical parameters of 11 brain metastases included in the study

| Cases | Age  | bPFS (months) | Neurological symptoms          | Number of brain lesion | Site of brain lesion                      | Treatment of brain metastases                     | bOS (months) |
|-------|------|---------------|--------------------------------|------------------------|------------------------------------------|--------------------------------------------------|-------------|
| 1     | 49   | 11            | NA                             | 1                     | Parietal lobe                            | Surgery, Chemotherapy                             | 6           |
| 2     | 57   | 68            | Confusional state              | 1                     | Occipital lobe                           | Surgery                                           | 42          |
| 3     | 70   | 29            | Ataxia                         | 1                     | Parieto-occipital lobe                   | Surgery WBRT                                      | 41          |
| 4     | 70   | 22            | Unilateral symptoms            | 1                     | Parietal lobe                            | Surgery Chemotherapy, EBRT                        | 6           |
| 5     | 50   | 18            | Headache, vertigo              | 2                     | Temporo-occipital lobe, frontal lobe     | Surgery Chemotherapy, EBRT                        | 29          |
| 6     | 70   | 28            | Aphasia, disorientation, dizziness | 1                     | Parietal lobe                           | Surgery, stereotactic radiotherapy                | 56          |
| 7     | 52   | 54            | NA                             | 1                     | Frontal lobe                            | Surgery Chemotherapy, EBRT                        | 7           |
| 8     | 62   | 15            | Headache, altered walking gait | 5                     | Temporal lobe, frontal lobe, occipital lobe | Surgery EBRT                                     | 3           |
| 9     | 46   | 23            | NA                             | 1                     | NA                                       | Surgery                                           | 3           |
| 10    | 72   | 18            | Ataxia, dysmetria              | 6                     | Frontal lobe (the major)                 | Surgery EBRT                                     | 7           |
| 11    | 74   | 25            | Vertigo                        | 1                     | Frontal lobe                            | Surgery EBRT                                     | 64          |

NA: not available; WBRT: Whole Brain Radiotherapy; bPFS: Progression Brain Metastasis Free Survival; bOS: Brain Metastasis Overall Survival.

Figure 1 shows the immune-histochemical profile of a representative case of serous ovarian carcinoma included in the Case dataset (Case 11, Table 2) and its matched brain metastasis of one.

Statistical analysis

Case dataset vs. Control dataset. Using a cut-off of 10%, only AR showed a significant difference of expression ($p=0.013$) between the two studied series: the risk to develop a brain metastasis appeared 9.5 times greater in patients with AR-negative primary ovarian cancer (Table 3a). Although at the limit for a statistical significant correlation, the HER2 expression in primary ovarian lesions was lower in patients who developed brain metastasis ($p=0.069$) (Table 3a). When considered as a continuous variable, AR retained its predictive role (mean Case dataset: 16.9; mean Control dataset: 40.5; $p=0.035$), as mainly expressed in primary ovarian tumors in the Control dataset (Table 3b). None of the other immune-histochemical biomarkers proved to be statistically significant (Table 3a and 3b). Cox multivariate analysis confirmed the lack of AR tumor expression in primary ovarian lesions as a negative independent prognostic parameter, supporting brain metastasis progression ($p=0.053$, CI 95% 1.000-1.073).

Primary ovarian cancers vs. matched brain metastases. No statistical differences were observed when biomarkers were considered as dichotomized variables (Table 3a). However, if considered as continuous variables, ER and AR showed a statistically significant greater expression in primary tumors in comparison with brain metastases ($p=0.013$, CI 95%=6.16-40.65 and $p=0.032$, CI 95%=1.12-19.08 respectively) (Table 4). Figure 2 shows the immunohistochemical profile of AR in primary and metastatic brain lesions of our “Case dataset”.

DISCUSSION

Currently small retrospective studies suggest that histology, stage of disease [13], loss of BRCA1 function...
Table 3a: Immunohistochemical results for hormonal receptors (ER, PR, AR categorised as dichotomised variables) and HER2 in Case dataset (both primary and metastatic lesions) and Control dataset: statistical analysis

| Immunohistochemistry | Cut-off          | Case dataset-primary ovarian tumors N/10* (%) | Case dataset-brain metastases N/11 (%) | Control dataset-primary ovarian tumors N/22 (%) | p (Cases vs. Controls: IHC comparison) | OR (Cases vs. Controls) (IC 95%) | p (Cases: primary vs. metastatic lesions: IHC comparison) |
|----------------------|------------------|---------------------------------------------|----------------------------------------|-------------------------------------------------|---------------------------------------|---------------------------------|-------------------------------------------------|
| **ER**               | < 1%             | 1 (10)                                      | 2 (18)                                 | 1 (5)                                           | 0.534                                 |                                 | 0.200                                           |
|                      | ≥ 1%             | 9 (90)                                      | 9 (82)                                 | 21 (95)                                         | 0.534                                 |                                 | 0.200                                           |
|                      | < 10%            | 1 (10)                                      | 3 (27)                                 | 2 (9)                                           | 1.000                                 |                                 | 0.300                                           |
|                      | ≥ 10%            | 9 (90)                                      | 8 (73)                                 | 20 (91)                                         | 1.000                                 |                                 | 0.300                                           |
| IRS ≤ 2              | 1 (10)                                      | 4 (36)                                      | 2 (9)                                           | 1.000                                           | 0.400                                 |                                 | 0.400                                           |
| IRS > 2              | 9 (90)                                      | 7 (64)                                      | 20 (91)                                         | 1.000                                           | 0.400                                 |                                 | 0.400                                           |
| **PR**               | < 1%             | 7 (70)                                      | 9 (82)                                 | 11 (50)                                         | 0.446                                 |                                 | 1.000                                           |
|                      | ≥ 1%             | 3 (30)                                      | 2 (18)                                 | 11 (50)                                         | 0.446                                 |                                 | 1.000                                           |
|                      | < 10%            | 7 (70)                                      | 10 (91)                                | 13 (59)                                         | 0.703                                 |                                 | 0.300                                           |
|                      | ≥ 10%            | 3 (30)                                      | 1 (9)                                  | 9 (41)                                         | 0.703                                 |                                 | 0.300                                           |
| IRS ≤ 2              | 7 (70)                                      | 10 (91)                                     | 13 (59)                                         | 0.703                                           | 0.300                                 |                                 | 0.300                                           |
| IRS > 2              | 3 (30)                                      | 1 (9)                                       | 9 (41)                                         | 0.703                                           | 0.300                                 |                                 | 0.300                                           |
| **AR**               | < 1%             | 3 (30)                                      | 6 (55)                                 | 2 (9)                                           | 0.293                                 |                                 | 1.000                                           |
|                      | ≥ 1%             | 7 (70)                                      | 5 (45)                                 | 20 (91)                                         | 0.293                                 |                                 | 1.000                                           |
|                      | < 10%            | 6 (60)                                      | 8 (73)                                 | 3 (14)                                         | 0.013                                 | 9.5 (1.64 - 54.99)                  | 0.133                                           |
|                      | ≥ 10%            | 4 (40)                                      | 3 (27)                                 | 19 (86)                                         | 0.013                                 |                                 | 0.133                                           |
| IRS ≤ 2              | 7 (70)                                      | 10 (91)                                     | 10 (45)                                         | 0.265                                           |                                 |                                 | 0.300                                           |
| IRS > 2              | 3 (30)                                      | 1 (9)                                       | 12 (55)                                         | 0.265                                           |                                 |                                 | 0.300                                           |
| **HER2**             | 0                | 9 (90)                                      | 7 (64)                                 | 14 (63)                                         | 0.693                                 | 1.6 (0.15 - 17.22)                  | 0.364                                           |
| 1+                   | 0 (0)                                      | 3 (27)                                      | 5 (23)                                         | 0.693                                           |                                 |                                 | 0.364                                           |
| 2+                   | 0 (0)                                      | 1 (9)                                       | 3 (14)                                         | 0.693                                           |                                 |                                 | 0.364                                           |
| 3+                   | 1 (10)                                     | 0 (0)                                       | 0 (0)                                           | 0.693                                           |                                 |                                 | 0.364                                           |

* one case was excluded due the limited neoplastic tissue available.
ER: Estrogen Receptor; PR: Progesterone Receptor; AR: Androgen Receptor; HER2: Human Epidermal Growth Factor Receptor 2; IRS: Immunoreactive Score; OR: Odds Ratio.

Table 3b: Immunohistochemical results for hormonal receptors (ER, PR, AR considered as continuous variables) in Case dataset and Control dataset: statistical analysis

| Immunohistochemical parameters | Case vs. Control dataset | N   | Mean | Median | Range  | p     |
|-------------------------------|--------------------------|-----|------|--------|--------|-------|
| ER                            | Cases                    | 10  | 57.4 | 62.5   | 0-95   | 0.397 |
|                              | Controls                 | 22  | 67.1 | 75     | 0-95   | 0.442 |
| PR                            | Cases                    | 10  | 6.5  | 0      | 0-35   | 0.381 |
|                              | Controls                 | 22  | 11.5 | 0.5    | 0-75   | 0.381 |
| AR                            | Cases                    | 10  | 16.9 | 6.5    | 0-65   | 0.035 |
|                              | Controls                 | 22  | 40.5 | 32.5   | 0-90   | 0.035 |

ER: Estrogen Receptor; PR: Progesterone Receptor; AR: Androgen Receptor.
[23], MDR-1 tumor expression [24] may be associated with CNS progression in very small series of patients. In the present study we investigated the predictive role of AR, ER, PR and HER2.

Hormone receptor status has been extensively investigated in EOC patients, playing an important role in ovarian cancer pathogenesis [25], but the literature data appear still conflicting and above all not conclusive [15-22]. In a recent review, including 35 studies investigating the prognostic role of hormone receptors in EOC, ER failed to predict patients’ outcome, whereas elevated levels of PR and HER2 predicted favorable and worse survival, respectively [26]. AR tumor expression has been recently suggested to be a favourable prognostic parameter in

| Immunohistochemical parameters | Primary tumor vs. brain metastasis | Mean | Median | Range | p      |
|-------------------------------|-----------------------------------|------|--------|-------|--------|
| ER                            | Primary tumor                     | 57.4 | 62.5   | 0-95  | 0.013  |
|                               | Brain metastasis                  | 34   | 22.5   | 0-76  |        |
| PR                            | Primary tumor                     | 6.5  | 0      | 0-35  | 0.396  |
|                               | Brain metastasis                  | 3.1  | 0      | 0-30  |        |
| AR                            | Primary tumor                     | 16.9 | 6.5    | 0-65  | 0.032  |
|                               | Brain metastasis                  | 6.8  | 0      | 0-35  |        |

ER: Estrogen Receptor; PR: Progesterone Receptor; AR: Androgen Receptor.

Figure 1: Case 11 of the “Case dataset”: representative case of a serous high-grade ovarian cancer (A-E) (A: H&E, 10x): hormonal receptor status (B: ER=60%, 10x; C: PR=0%, 10x; D: AR=8%, 10x) and HER2 tumor expression (E: HER2 3+, 10x). Its derived brain resected metastasis (F-J) with the same morphological appearance (F: H&E, 10x): hormonal receptor status (G: ER=72%, 10x; H: PR=0%, 10x; I: AR=5%, 10x) and HER2 metastasis expression (J: HER2 2+, 10x).
Figure 2: AR tumor expression in primary and metastatic lesions of our “Case dataset”. From Case 1 to Case 10 (A, C: H&E, 10x/B-D: AR, 10x, Case 1; E, G: H&E, 10x/F, H: AR, 10x, Case 2; I, K: H&E, 10x/J, L: AR, 10x, Case 3; M, O: H&E, 10x/N, P: AR, 10x, Case 4; Q, S: H&E, 10x/R, T: AR, 10x, Case 5; U, W: H&E, 10x/V, X: AR, 10x, Case 7; Y, AA: H&E, 10x/Z-, AB: AR, 10x, Case 8; AC, AE: H&E, 10x/AD, AF: AR, 10x, Case 9; AG, AI: H&E, 10x/AH, AJ: AR, 10x, Case 10). Case 6 is not showed as excluded from the immunohistochemical analysis, due to insufficient residual cancer after neoadjuvant chemotherapy.
serous EOCs, especially when co-expressed with PR [27, 28]. Notably, AR is the only hormone receptor included in the five good-prognosis predictors of the protein-driven index of ovarian cancer (PROVAR), a protein-based panel able to predict time to EOC recurrence [29]. Due to the limited number of events, in the subgroup of EOC patients who developed CNS progression, hormonal receptor status role has not yet widely been explored.

In our case-control study, comparing patients who developed a CNS metastasis and patients who did not, we highlight a predictive role of AR. Specifically, patients with AR-negative EOC show a 9.5 times greater propensity to develop CNS metastases than AR-positive EOC (cut-off: 10%); moreover, when considered as continuous variable, AR retains its predictive value. Multivariate analysis confirms reduced AR expression in primary EOC as a negative independent predictive parameter. In a previous study, AR status has been reported to be associated with a prolonged ovarian cancer specific survival, underlining its favourable prognostic role [27], but our paper, for the first time, describe its predictive value in the subgroup of EOC metastatic to the brain. In the literature, different cut-off values have been considered in assessing the hormone receptor status positivity [16, 17, 22, 27, 28, 30], reason that could partially explain the discrepancy observed among the different works. Thus, to bypass this impasse and achieve a clearer view of the data, we consider different cut-off of positivity, according to literature and in particular 1%, 10% or IRS [16-22, 27, 28, 30]. The AR cut-off point of 10% in primary ovarian lesion seems to be the best predictor of brain progression in EOC patients. Therefore, EOC primary tumors that express AR are lower prone to cerebral spread. This observation may be in agreement with other recent studies stressing the favourable prognostic role of AR identifying a subgroup of patients with better survival in ovarian, breast and endometrial cancers, founding the basis to an endocrine anti-AR therapeutic approach [27, 28, 31-33].

In our study, a low or none tumor expression of HER2 identifies a subgroup of EOC patients with higher risk to develop brain metastases even if with a borderline statistical significance, probably related to the small number of analysed cases. In general, very few data are reported in literature regarding HER2 prognostic/predictive role in EOC, although its overexpression seems to be related to worse patient’s outcome [30, 34, 35]. In this setting, our observation could seem in contrast with previous reports [26, 30, 34, 35], but we might speculate that as brain progression represent a rare and late event in EOC natural history [13], it could be possible that patients with HER2 overexpression die before brain metastatic dissemination.

Almost no data are reported in literature about protein expression profile assessment in brain metastases from EOC: the only, to our knowledge, is the paper by Yoshida et al. including a single case of matched primary and metastatic lesion [36]. The reason for this scarcity may rely on both the rarity of the event and of the surgery, as only 30% of patients [3, 13] undergo brain metastatic resection. Thus, our paper is the first reported work that focused on investigation of protein expression profile in a consecutive case series of EOC and their matched brain metastases. Considering hormone receptors status as continuous variables, we observed a significant difference between primary and brain lesions in expressing ER (57.4% vs. 34%, p = 0.013) and AR (16.9% vs. 6.8%, p = 0.032). Specifically, a reduction of both receptors has been detected in metastatic tissue. Since CNS progression is clearly an adverse prognostic feature, our results are consistent with previously reported good prognostic role of AR, as the tumors seem to lose AR protein expression during the metastatic spread to brain. A progressive ‘de-differentiation’ of neoplastic cells could be hypothesized.

In conclusion, the increased incidence of CNS metastases from EOC underlines the importance of identifying predictive biomarkers tightly associated with CNS progression. The identification of patients at higher risk to develop CNS metastases may help to improve prognosis and quality of life, as previously extensively reported [3, 4, 6, 8, 10, 11, 13]. Although the present case-control study is the biggest ever reported in literature, in terms the number of enrolled patients and the possibility to analyse EOC and their matched brain metastasis, a validation in larger series is likely.

MATERIALS AND METHODS

Patient’s collection

From a consecutive, retrospective and multi-institutional series of 1092 patients who underwent surgery for brain metastases resection between January 1998 and December 2013, a cohort of 24 patients with CNS metastases developed from a primary, histologically confirmed EOC was extrapolated. The initial cohort was retrieved from the Pathology archives of the Hospitals included in the Neuro-Oncological Network of the Piedmont Region-Italy (AOU Città della Salute e della Scienza di Turin, AO San Giovanni Bosco Hospital of Turin, AOU Maggiore della Carità of Novara, AO S.Croce e Carle Hospital of Cuneo, AO SS. Antonio, Biagio and Cesare Arrigo of Alessandria). Essential inclusion criteria for the study were the availability of both i) paraffin-embedded tissue blocks (corresponding to primary ovarian lesion and its matched brain metastasis) and ii) follow-up data, thus 13/24 cases were excluded; therefore, a series of 11 patients was finally collected representing our “Case dataset”. For each patient, clinico-histopathological data were obtained by medical records. The following parameters were recorded: i) age at diagnosis; ii) date of primary tumor and CNS metastasis diagnosis; iii) morphological features of ovarian and brain
metastasis as tumor histotype and grade (according to World Health Organization Classification of Tumours of Female Reproductive Organs, 4th Edition); iv) date and site of first relapse; v) type of patient’s treatment; vi) date of death or last follow up (FU). OS was determined as the time from the date of EOC diagnosis to the date of patient death or last FU, whereas progression free survival (PFS) as the time from the EOC diagnosis to the date of first clinical relapse. In addition, we calculated the Progression Brain Metastasis Free Survival (bPFS) as the time from the date of ovarian cancer first diagnosis to brain metastasis, and the Brain Metastasis Overall Survival (bOS) as the time from the date of brain metastasis diagnosis to death or last FU.

For comparison, we evaluated a second series of 22 cases, named “Control dataset”, extracted from the clinical records of Candiolo Cancer Institute, including patients with a diagnosis of ovarian cancer who had not developed brain metastasis after a median FU of 38.5 months (range 6-82 months). In order to statistically compare the two subgroups and to avoid confounders, Cases were paired with Controls with a 1:2 ratio, according to the following three clinico-pathological parameters: tumor grade, clinical tumor stage and residual disease after surgery (present vs. absent). The same clinico-morphological features collected for the Case dataset were also obtained for this subgroup of patients.

The study was submitted to and approved by the Ethic Institutional Review Board for “Biobanking and use of human tissues for experimental studies” of the Pathology Service of the AOU Città della Salute e della Scienza (Turin, Italy). The project provided a verbal and not written informed consent from the patients due to the retrospective approach of the study, which did not impact on their treatment. All the cases were anonymously recorded. The Institutional Review Board approved this consent procedure.

Immunohistochemistry procedures

The most representative paraffin block was selected for each lesion and immune-histochemical analysis was performed in all cases. Three-micrometer-thick serial paraffin sections were prepared and routinely stained with Hematoxylin and Eosin (H&E); additional sections, collected on superfrost plus slides, were used for immune-histochemical analysis. Immune-histochemical reactions using antibodies anti-ER (monoclonal antibody, clone SP1, pre-diluted, Ventana, Roche); anti-PR (monoclonal antibody, clone 16, diluted 1:100, Novocastra™ Leica); anti-AR (monoclonal antibody, clone SP107, pre-diluted, Ventana, Roche), and anti-HER2 (rabbit monoclonal antibody, clone 4B5, pre-diluted, Ventana, Roche) were performed in an automated immunostainer (VentanaBenchMark XT AutoStainer, Ventana Medical Systems, Tucson, AZ, USA). Appropriate positive and negative controls were included for each immune-histochemical run.

Staining interpretation

Two observers, who were blinded to clinical data, independently evaluated the staining results. Hormone receptors were considered as follows: i) continue variable (number of positive neoplastic cells considered as a percentage ranging from 0 to 100%), ii) discrete variable using cut-off of 1% [30, 31, 37] and 10% [16, 17, 22, 27, 28, 38] as previously reported in literature, and iii) dichotomised variable according to the recently reported Immunoreactive Score (IRS) [18-21]. HER2 status was assessed according to ASCO/CAP recommendations (2013) for breast cancer [39].

Statistical analysis

All statistical analyses were performed using SPSS software for Windows (version 22.0; SPSS Inc., Chicago, IL). Quantitative variables were initially compared with Pearson Chi-square test, but due to the small number of cases results are not reliable. Therefore Fisher exact test has been considered for the further statistical analyses. Qualitative variables were compared using analysis of variance (ANOVA) or dependent T test for paired samples. Multivariate analysis was performed using regression analysis. P values <0.05 were considered significant, and all tests were two-tailed.

Author contributions

GM: data analysis and interpretation, manuscript preparation, manuscript review; RS: data analysis and interpretation, manuscript editing, manuscript review; GS: data analysis and interpretation, manuscript review; MA: study concept and manuscript review; FM: quality data control and statistical analysis; EG: data analysis and interpretation, manuscript review; SG: data analysis and interpretation, manuscript review; RB: data analysis and interpretation and manuscript review; CM: data analysis and manuscript review; IM: data analysis and manuscript review; RB: manuscript review; AS: data analysis and manuscript review; PC: study concept, study design, data analysis and interpretation, manuscript editing and manuscript review; GV: study concept, study design, data analysis and interpretation, manuscript editing and manuscript review.

ACKNOWLEDGMENTS

We thank Dr. Alberto Pisacane for helpful discussion.
CONFLICTS OF INTEREST

All authors declare that they have no conflicts of interest.

FUNDING

This work has been supported by the following grant to GV: VALG_RIC_LOC_14_01 and to PC: Rete OncologicaPiemonte e Valle d’Aosta and Ministry of the University (ex 60%, 2015).

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7-30. doi: 10.3322/caac.21332.
2. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003; 13: 125-9.
3. Piura E, Piura B. Brain metastases from ovarian carcinoma. ISRN Oncol. 2011; 2011: 527453. doi: 10.5402/2011/527453.
4. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstatihu E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005; 25: 3553-8.
5. Hardy JR, Harvey VJ. Cerebral metastases in patients with ovarian cancer treated with chemotherapy. Gynecol Oncol. 1989; 33: 296-300.
6. Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol. 2004; 66: 313-25.
7. Kolomainen DF, Larkin JM, Badran M, A’Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol. 2002; 20: 982-6.
8. Pectasides D, Pectasides M, Economopoulos T. Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist. 2006; 11: 252-60. doi: 10.1634/theoncologist.11-3.252.
9. Kim TJ, Song S, Kim CK, Kim WY, Choi CH, Lee JH, Lee JW, Bae DS, Kim BG. Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2007; 17: 1252-7. doi: 10.1111/j.1525-1438.2007.00941.x.
10. Cormio G, Loizzi V, Falagario M, Calace A, Colamaria A, De Tommasi A, Selvaggi LE. Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes. Int J Gynecol Cancer. 2011; 21: 816-21. doi: 10.1097/IGC.0b013e318216ca0d.
11. Kasritsis E, Efstatihu E, Gika D, Bozas G, Koutsoukou V, Papadimitriou C, Pissakas G, Dimopoulos MA, Bamias A. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer. 2006; 16: 994-9. doi: 10.1111/j.1525-1438.2006.00596.x.
12. Nasu K, Satoh T, Nishio S, Naga Y, Ito K, Osuki T, Hongo A, Hirashima Y, Ogura T, Shimada M. Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial). Gynecol Oncol. 2013; 128: 198-203. doi: 10.1016/j.ygyno.2012.11.001.
13. Pakneshan S, Safarpour D, Tavassoli F, Jabbari B. Brain metastasis from ovarian cancer: a systematic review. J Neurooncol. 2014; 119: 1-6. doi: 10.1007/s11060-014-1447-9.
14. Marchetti C, Ferrandina G, Cormio G, Gambino A, Cecere S, Lorusso D, De Giorgi U, Bogliolo S, Fagotti A, Mammoliti S, Narducci F, Bergamini A, Scillo P, et al. Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). Gynecol Oncol. 2016; 143: 532-538. doi: 10.1016/j.ygyno.2016.09.025.
15. Voutsadakis IA. Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations. Clin Med Insights Oncol. 2016; 10: 17-25. doi: 10.4137/CMO.S32813.
16. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005; 96: 671-7. doi: 10.1016/j.ygyno.2004.11.010.
17. Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007; 18: 1051-9.
18. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H, Surowiak P. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 2011; 17: 511-8. doi: 10.1007/s11060-014-1447-9.
19. Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, Frieske K, Jeschke U. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012; 12: 553. doi: 10.1186/1471-2407-12-553.
20. Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reithaller A, Polterauer S. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1)
expression in ovarian cancer. BMC Cancer. 2013; 13: 115. doi: 10.1186/1471-2407-13-115.

21. Tkalia IG, Vorobyova LI, Svintsitsky VS, Nespryadko SV, Goncharuk IV, Lukyanova NY, Chekhun VF. Clinical significance of hormonal receptor status of malignant ovarian tumors. Exp Oncol. 2014; 36: 125-33.

22. van Kuilenburg B, de Groot M, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hospers G, Reinders A. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138: 634-9. doi: 10.1016/j.ygyno.2015.06.032.

23. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-95. doi: 10.1200/JCO.2009.25.6529.

24. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010; 124: 607-17. doi: 10.1007/s13577-012-0053-4.

25. Demir L, Yigit S, Sadullahoglu C, Akyol M, Cokmert S, Kucukzeybek Y, Alacacioglu A, Cakalagaoglu F, Tarhan MO. Hormone receptor, HER2/NEU and EGFR expression in ovarian cancer--is here a prognostic phenotype? Asian Pac J Cancer Prev. 2014; 15: 9739-45.

26. Nodin B, Zendehrokh N, Brändstedt J, Nilsson E, Manjer J, Brennan DJ, Jirström K. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010; 3: 14. doi: 10.1186/1757-2215-3-14.

27. Jönsson JM, Skovbjerg Arildsen N, Malander S, Måsbäck J, Brändstedt J, Nilsson E, Manjer J, Brennan DJ, Jirström K. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010; 3: 14. doi: 10.1186/1757-2215-3-14.

28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, et al. Recommendations for human epithelial factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31: 3997-4013. doi: 10.1200/JCO.2013.50.9984.

29. Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K. Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res. 2013; 39: 292-6. doi: 10.1111/j.1447-0756.2012.01961.x.

30. Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenheim NB, Sood AK. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011; 34: 488-93. doi: 10.1097/COC.0b013e3181ec5f4b.

31. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998; 90: 1774-86.

32. Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013; 23: 25-33. doi: 10.1097/IGC.0b013e3182788466.

33. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Takano M, Ushijima K, Taniy JL, Coukos G, Lu Y, Mills GB, Verhaak RG, et al. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013; 123: 3740-50. doi: 10.1172/JCI68509.

34. Qu Q, Mao Y, Fei XC, Shen KW. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013; 8: e82650. doi: 10.1371/journal.pone.0082650.

35. Kamal AM, Bulmer JN, DeCruze SB, Stringfellow HF, Martin-Hirsch P, Hapangama DK. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br J Cancer. 2016; 114: 688-96. doi: 10.1038/bjc.2016.16.

36. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005; 68: 154-61. doi: 10.1172/JCI68509.